Prescient Therapeutics (ASX:PTX) raised around AU$4.8 million via its share purchase plan and around AU$1.2 million in the shortfall placement, according to a Wednesday Australian bourse filing.
The issue price under the share purchase plan and the placement was AU$0.065 apiece. Around 18.5 million new shares are expected to be issued under the placement.
The proceeds will provide additional funding for the continued development of its PTX-100 treatment candidate beyond the first dose optimization committee review.
Its shares fell 2% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments